China Daily Global Edition (USA)

Revival WORLD hopesUSA

- By MAY ZHOU in Houston mayzhou@chinadaily­usa.com

Thailand Pfizer COVID-19 looking shot to shift gets from mass full approval tourism by to big US spenders FDA

Biden calls it a ‘key milestone’ in fight against COVID-19, urges hesitant to get vaccinated

The US Food and Drug Administra­tion (FDA) on Monday granted full approval to Pfizer-BioNTech’s COVID-19 vaccine for people 16 and older, a move that is expected to pave the way for public and private entities to mandate vaccinatio­ns and help persuade hesitant Americans to be more receptive to getting vaccinated.

“Today marks a key milestone in our nation’s fight against COVID,” President Joe Biden said after the approval was announced. “Those who have been waiting for full approval should go get your shots now. The vaccinatio­n is free, it’s easy, it’s safe, it’s effective, and it’s convenient.”

Biden said that 90 percent of Americans can get the vaccinatio­n within 5 miles of their homes without an appointmen­t. He said that the Delta variant is dangerous and spreading, especially among the unvaccinat­ed.

Vaccinatio­n is working, Biden said. “Even though the Delta variant is ravaging the unvaccinat­ed, the death rate is 70 percent lower than in last winter,” he declared.

Pfizer’s vaccine was first approved for emergency use in December last year. It continues to be available under emergency use authorizat­ion for young people 12 through 15 years old and for the administra­tion of a third booster shot for immunocomp­romised individual­s.

Pfizer plans to market the vaccine under the name Comirnaty. It took the FDA less than four months to grant Pfizer the approval while the normal timeframe is about 10 months.

“The public and medical community can be confident that although we approved this vaccine expeditiou­sly, it was fully in keeping with our existing high standards for vaccines in the US,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

The FDA analyzed effectiven­ess data from approximat­ely 20,000 vaccine recipients and 20,000 placebo recipients ages 16 and older. Based on results from the clinical trial, the vaccine was 91 percent effective in preventing COVID-19.

“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated,” Dr Janet Woodcock, the acting FDA commission­er, said in a statement. “Today’s milestone puts us one step closer to altering the course of this pandemic in the US.”

Pfizer plans to request booster authorizat­ion as well as full approval for young people age 12-15. Moderna, whose vaccine under emergency use authorizat­ion adopts similar mRNA technology, is in the process of completing data submission for its request for full approval. Johnson & Johnson plans to file for full approval later.

The full approval came as the Delta variant is driving up infection rates and COVID-19 patients are filling hospitals across the country.

Since the beginning of the pandemic, more than 37.8 million Americans have been infected, and more than 628,000 have died from COVID-19, according to Johns Hopkins University.

Currently the seven-day average daily death rate is roughly 1,008, according to New York Times.

The Pentagon said after the FDA announceme­nt about the Pfizer vaccine that Defense Secretary Lloyd Austin will be sending guidelines to the country’s 1.4 million active-duty service members mandating vaccines.

New York City officials announced Monday that all teachers, principals and custodians will be required to get at least one dose of a COVID-19 vaccine by Sept 27. The mandate will affect about 148,000 city employees in the nation’s largest public school system, with about 1.1 million students.

The infection and death uptick related to COVID-19 seems to have softened some people’s attitude toward the vaccine.

A recent survey conducted on Aug 2 by the US Census Bureau showed that 10.5 percent of US adults 18 years and old are hesitant to receive a COVID-19 vaccine. In mid-January, 21.6 percent were reluctant to get the vaccine.

Resistance to receiving vaccines varies greatly from state to state. In Wyoming, 25.2 percent adults said they will likely or definitely decline vaccines. In contrast, only 3.7 percent harbor the same reluctancy in Massachuse­tts.

Consequent­ly, 37.7 percent of Wyoming’s population and 64.9 percent of Massachuse­tts’ population are fully vaccinated.

 ??  ??

Newspapers in English

Newspapers from United States